Olivier Litzka
Director/Miembro de la Junta en JenaValve Technology GmbH .
Fortuna: - $ al 31/05/2024
Origen de la red de primer grado Olivier Litzka.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France.
91
| Private Company | Investment Managers | 91 |
JenaValve Technology, Inc.
 JenaValve Technology, Inc. Medical SpecialtiesHealth Technology JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.
12
| Holding Company | Medical Specialties | 12 |
Medlumics SL
 Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain.
10
| Holding Company | Medical Specialties | 10 |
| Public Company | Biotechnology | 9 | |
JenaValve Technology GmbH
 JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.
9
| Subsidiary | Medical Specialties | 9 |
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.
9
| Subsidiary | Biotechnology | 9 |
Ariceum Therapeutics GmbH
 Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
| Public Company | Biotechnology | 6 | |
T-Knife GmbH
 T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany.
6
| Holding Company | Biotechnology | 6 |
HighLife SAS
 HighLife SAS Medical SpecialtiesHealth Technology HighLife SAS develops percutaneous mitral valve replacement therapies. It offers a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded by Georg Börtle in 2010 and is headquartered in Paris, France.
5
| Holding Company | Medical Specialties | 5 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Olivier Litzka a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| École des Hautes Études Commerciales de Paris | College/University | Masters Business Admin Graduate Degree Graduate Degree Graduate Degree Graduate Degree Graduate Degree Undergraduate Degree Graduate Degree Graduate Degree Undergraduate Degree | |
| TME PHARMA N.V. | Biotechnology | Director/Board Member Chairman Director/Board Member Founder Chairman Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| ESCP Europe Campus Paris | College/University | Graduate Degree Graduate Degree Graduate Degree Undergraduate Degree Graduate Degree | |
| Université Paris Dauphine-PSL | College/University | Graduate Degree Graduate Degree Undergraduate Degree Graduate Degree Undergraduate Degree | |
| EM Lyon Business School | College/University | Undergraduate Degree Graduate Degree Graduate Degree Graduate Degree | |
| Harvard Business School | College/University | Corporate Officer/Principal Masters Business Admin Masters Business Admin | |
| AXONICS, INC. | Medical Specialties | Director/Board Member Chairman Founder | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Chairman Director/Board Member | |
GamaMabs Pharma SA
 GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | Medical/Nursing Services | Director/Board Member Chairman Director/Board Member | |
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| Sciences Po | College/University | Graduate Degree Undergraduate Degree Graduate Degree | |
Synacktiv SAS
 Synacktiv SAS Information Technology ServicesTechnology Services Synacktiv SAS provides cyber security services. The company is based in Paris, France. The French company was founded in 2012 by Nicolas Collignon, Renaud Feil. Renaud Feil has been the CEO since 2012. | Information Technology Services | Director/Board Member Director/Board Member Director/Board Member | |
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Private Equity Investor Private Equity Investor Chairman | |
| ESSEC Business School | College/University | Graduate Degree Graduate Degree Graduate Degree | |
| University of Oxford | College/University | Graduate Degree Doctorate Degree | |
Neomed Management AS
 Neomed Management AS Investment ManagersFinance Neomed Management AS is an investment firm based in Oslo. Founded in 1998, the firm specializes in private equity investments in the healthcare and life science sectors. Neomed advises several funds namely NeoMed I, II, III, IV and V. | Investment Managers | Founder Consultant / Advisor | |
| Universidad Politécnica de Madrid | College/University | Graduate Degree Graduate Degree | |
Zhuhai Seine Technology Co., Ltd.
 Zhuhai Seine Technology Co., Ltd. Computer PeripheralsElectronic Technology Zhuhai Seine Technology Co., Ltd. is a holding company that manufactures printers and supplies printer consumables. It offers single funcation and multifunction printers, printer cartridges such as inkjet, laser and ribbon, and packaging . The company was founded by Jackson Wang on April 24, 2006 and is headquartered in Zhuhai, China. | Computer Peripherals | Director/Board Member Director/Board Member | |
Goldman Sachs & Co. LLC
 Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Investment Banks/Brokers | Analyst-Equity Corporate Officer/Principal | |
Legend Capital Co. Ltd.
 Legend Capital Co. Ltd. Investment ManagersFinance Legend Capital Co. Ltd (Legend Capital) is a private equity venture capital subsidiary of Legend Holdings Corp. founded in 2001 by Zhu Li Nan. The firm is headquartered in Beijing, China. | Investment Managers | Director/Board Member Chief Executive Officer | |
| Imperial College London | College/University | Graduate Degree Undergraduate Degree | |
| LOGICBIO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
| Institut d'Études Politiques d'Aix-en-Provence | College/University | Graduate Degree Graduate Degree | |
| University of Oslo | College/University | Doctorate Degree Doctorate Degree | |
| WEIFA ASA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Stanford Graduate School of Business | College/University | Graduate Degree Graduate Degree | |
CorWave SA
 CorWave SA Medical SpecialtiesHealth Technology CorWave SA develops and manufactures blood pumps. The company was founded in 2011 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member Director/Board Member | |
| SEQUANA MEDICAL N.V. | Medical Specialties | Director/Board Member Director/Board Member | |
| ISOFOL MEDICAL AB | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
Corflow Therapeutics AG
 Corflow Therapeutics AG Medical SpecialtiesHealth Technology Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz. | Medical Specialties | Founder Director/Board Member | |
| Université Paris Nanterre | College/University | Graduate Degree Graduate Degree | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Affectis Pharmaceuticals AG
 Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
| ROCHE HOLDING AG | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal | |
| RADIUS HEALTH, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| Ecole Polytechnique | College/University | Undergraduate Degree Doctorate Degree | |
Altavia France SA
 Altavia France SA Advertising/Marketing ServicesCommercial Services Altavia France SA is an investment holding company with interest in marketing and advertising sector. The company was founded on September 1, 1954 and is headquartered in Saint-Ouen-Sur-Seine, France. | Advertising/Marketing Services | Director/Board Member Director/Board Member | |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Walor International SAS
 Walor International SAS Metal FabricationProducer Manufacturing Walor International SAS manufactures precision machine components for the automotive industry. Its expertise includes cold forging, machining, and thermal treatment. The company was founded by Jacky Lorin and Jim Wallart in June 1993 and is headquartered in Lege, France. | Metal Fabrication | Director/Board Member Director/Board Member | |
| LSP Services Deutschland GmbH | Investment Managers | Private Equity Investor President | |
TCR Capital SAS
 TCR Capital SAS Investment ManagersFinance TCR Capital SAS is an independent private equity investment firm wholly-owned by management. Based in Paris, TCR is a lower mid-market specialist established in 1989 as the European office of US-based Quilvest. The firm launched their first fund in 1996, and in 2000 restricted their focus to France. As the management gradually increased their shareholding, the firm became independent in 2003 and wholly-owned in 2007. TCR manages a series a private equity funds. Their clients are French and European institutions and family offices. | Investment Managers | Corporate Officer/Principal Private Equity Analyst | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Doctorate Degree |
Estadísticas
Internacional
| Francia | 22 |
| Estados Unidos | 9 |
| Alemania | 6 |
| Suiza | 4 |
| Noruega | 4 |
Sectorial
| Health Technology | 23 |
| Consumer Services | 18 |
| Finance | 7 |
| Health Services | 2 |
| Technology Services | 2 |
Operativa
| Director/Board Member | 537 |
| Chairman | 87 |
| Corporate Officer/Principal | 87 |
| Private Equity Investor | 80 |
| Independent Dir/Board Member | 78 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Antoine Papiernik | 48 |
| Raphaël Wisniewski | 45 |
| Claus Asbjørn Andersson | 41 |
| Peter Barrett | 38 |
| Per Anders Göte Samuelsson | 36 |
| Joseph deBethizy | 29 |
| Patrick van Beneden | 28 |
| Hubert Birner | 27 |
| Denis Lucquin | 26 |
| Casey Tansey | 24 |
| Erik Amble | 23 |
| Joachim Rothe | 22 |
| Manfred Rüdiger | 22 |
| Andrew Hack | 20 |
| Martin C. Münchbach | 20 |
- Bolsa de valores
- Insiders
- Olivier Litzka
- Conexiones Empresas
